Vizsgálati helyszín
Malopolskie Centrum Kliniczne
Cracow, 30-149, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 22futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 36 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis22 vizsgálat
- 2. fázis8 vizsgálat
- 1. fázis4 vizsgálat
- 4. fázis2 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz11 vizsgálat
- Még nem toboroz6 vizsgálat
- Toboroz5 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- AbbVie7 vizsgálat
- Cullinan Therapeutics Inc.3 vizsgálat
- Horizon Therapeutics Ireland Designated Activity Company3 vizsgálat
- MoonLake Immunotherapeutics AG3 vizsgálat
- Amgen2 vizsgálat
- és még 16
Futó vizsgálatok
Toboroz
A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
NCT07667569· 2. fázis· Idorsia Pharmaceuticals Ltd.· Forrás
Toboroz
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· 3. fázis· Novo Nordisk A/S· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690· 2. fázis· Galderma R&D· Forrás
Toboroz
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
NCT07235904· 4. fázis· University Hospital Schleswig-Holstein· Forrás
Toboroz
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099· 1. fázis· Cullinan Therapeutics Inc.· Forrás
Toboroz
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446· 2. fázis· AbbVie· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· 2. fázis· Inmagene LLC· Forrás
Toboroz
A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)
2024-519114-31-00· 1. fázis· Cullinan Therapeutics Inc.· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239· 2. fázis· Zura Bio Inc· Forrás
Toboroz
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796· 3. fázis· Pfizer· Forrás
Toboroz
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360· 1. fázis· Cullinan Therapeutics Inc.· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· 3. fázis· AbbVie· Forrás
Toboroz
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· 3. fázis· Nektar Therapeutics· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· 3. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· 1. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· 3. fázis· Amgen· Forrás
Lezárult
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE
2023-505050-18-00· 4. fázis· Charite Universitaetsmedizin Berlin KöR· Forrás
Leállították
Hidradenitis Suppurativa Study of Izokibep
NCT05905783· 3. fázis· ACELYRIN Inc.· Forrás
Lezárult
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971· 3. fázis· LG Chem· Forrás
Lezárult
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
NCT04781543· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Lezárult
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics
of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
2023-509782-20-00· 2. fázis· Horizon Therapeutics Ireland Designated Activity Company· Forrás
Lezárult
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT04636801· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Fut, nem toboroz
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823· 3. fázis· AbbVie· Forrás
Hibát jelzek